Structure‐Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off‐Target Effects

Documenti analoghi

• Discovery of Palindrome Dual PPARγ‐GPR40 Agonists for Treating Type 2 Diabetes
  di: Ana Rodríguez‐Luévano, et al.
  Pubblicazione: (2024)
• Discovery of Novel Aminopyrimidines as Selective EP2 Receptor Antagonists
  di: Isabelle Lyothier, et al.
  Pubblicazione: (2025)
• Design, Synthesis, and Biological Assessment of Novel Aminobenzidazole Agonists Targeting the Stimulator of Interferon Genes (STING) Receptor Signaling Pathway for Oncology Immunotherapy
  di: Yiqing Fan, et al.
  Pubblicazione: (2025)
• Enhancing Drug Repurposing with Consensus Docking: Discovery of Novel Discoidin Domain Receptor 1 Inhibitors
  di: Jochem Nelen, et al.
  Pubblicazione: (2026)
• Discovery and in vitro Evaluation of Novel Serotonin 5‐HT2A Receptor Ligands Identified Through Virtual Screening
  di: Agata Zięba, et al.
  Pubblicazione: (2024)